Weight Maintenance After GLP‑1 Treatment

A narrative review of weight regain, clinical follow-up, and practical planning after the last injection

Dr. Wellness | Health Education

Abstract

GLP‑1–based medicines can produce substantial weight loss during treatment, but maintaining that loss after treatment ends can be challenging. Follow-up studies of semaglutide and tirzepatide show that participants regained weight on average after stopping, although the magnitude and timing varied. This narrative review summarises selected clinical studies and guidance, explains how to interpret the findings, and outlines what patients and clinicians can discuss before the final dose. It also addresses GluSlim, an herbal supplement sold by Dr. Wellness, and the lack of established evidence for its use in weight maintenance after GLP‑1 treatment. 2026 systematic review in The BMJ · NICE guidance on support after treatment

1. Introduction

During treatment, a weekly injection gives weight management a predictable rhythm. After the last dose, patients may have fewer points of contact with their care team just as they begin to notice changes in appetite or weight. For someone stopping because of side effects or cost, that transition may also happen sooner than expected. Planning for it means deciding who will follow up, what changes to monitor, and what support is available if weight begins to return. NICE guidance on prescribing and stopping weight-management medicines

The evidence discussed here includes semaglutide, a GLP‑1 receptor agonist, and tirzepatide, which acts on both GIP and GLP‑1 receptors. The studies used different designs and measured weight change in different ways. Reading those results in context helps explain what patients might expect and where the evidence remains uncertain. STEP 1 trial extension · SURMOUNT‑4 randomized clinical trial

2. What happens to weight after treatment stops?

Semaglutide. The STEP 1 extension followed a subset of adults with overweight or obesity who did not have diabetes. One year after weekly semaglutide and the trial’s structured lifestyle intervention ended, participants who had received semaglutide had regained about two-thirds of their earlier weight loss, on average. Several measures of cardiometabolic health also moved back toward their pretreatment levels. Because medication and structured lifestyle support ended at the same time, the study cannot tell us how much regain might have occurred if that support had continued. Wilding et al., STEP 1 trial extension

Tirzepatide. SURMOUNT‑4 addressed a related question using a randomized withdrawal design. After 36 weeks of tirzepatide, 670 participants were randomly assigned to continue the medicine or switch to placebo for 52 weeks. From the point of randomization, body weight increased by 14.0% on average in the placebo group and decreased by a further 5.5% in the group that continued tirzepatide. The 14.0% figure refers to the change in body weight from randomization. The STEP 1 figure, by contrast, describes the share of earlier weight loss that participants regained. Each result answers a different question. Aronne et al., SURMOUNT‑4 trial

The broader evidence. A 2026 systematic review and meta-analysis in The BMJ examined 37 studies of weight-management medications. Across the medicines studied, the estimated average rate of regain was about 0.4 kg per month after treatment ended. The studies included different medications and follow-up periods, so the pooled figure is best read as a population estimate. An individual’s weight can change at a different pace, and the estimate cannot tell a patient what will happen in any given month. West et al., 2026 systematic review

3. What the evidence can tell us about maintenance

Taken together, the studies make a strong case for treating the period after discontinuation as part of long-term care. They are less conclusive about which maintenance strategy works best once someone has stopped. STEP 1 followed a subset of its original participants, and SURMOUNT‑4 randomized people who reached the end of its initial treatment period. Both trials excluded people with diabetes. Their findings help set expectations, while decisions about follow-up, glucose monitoring, and alternative treatments need to account for each patient’s circumstances. STEP 1 trial extension · SURMOUNT‑4 randomized clinical trial

This distinction matters when discussing appetite and weight regain. A patient who notices that lunch no longer keeps them full until dinner has useful information to bring to a follow-up. So does someone whose weight starts rising despite keeping a familiar routine. Those observations can help a clinician or dietitian decide what to review, from meal timing and nutrition support to whether the treatment plan needs another look. NICE guidance on diet, activity, and long-term support

4. Building a maintenance plan before the final dose

Agree on follow-up. Ask your prescriber when to check in, what to monitor between appointments, and which changes should prompt an earlier call. If the medication also helps manage type 2 diabetes, discuss how blood glucose will be monitored and whether your diabetes treatment needs review. If side effects, cost, or availability are driving the decision, raise those concerns directly. They help determine which next steps are realistic. NICE guide to prescribing and monitoring weight-management medicines

Choose routines that fit the week you actually have. A maintenance plan should survive a late meeting, a family dinner, or a week when cooking feels like one more thing to do. If skipping lunch leaves you hungry by evening, start by making lunch easier to arrange. Leftover daal and roti with yoghurt, for instance, might be a meal you can bring to work. If an evening workout rarely happens, a regular walk after dinner might be easier to keep up. The aim is to find eating and activity routines that suit your health, preferences, and schedule. NICE guidance on physical activity and diet

Decide how to respond to change. If you and your clinician agree that weighing yourself would help, decide how often to check and what trend warrants a conversation. Appetite, meal routines, and blood glucose readings where relevant can add context. The UK’s National Institute for Health and Care Excellence recommends regular monitoring and feedback for at least a year after stopping weight-management medicines or completing a behavioural programme. It helps to leave the appointment knowing who you can call between visits and how to reach them. NICE quality standard on support after treatment

5. GluSlim and the Evidence on Weight Maintenance

GluSlim is an herbal supplement sold by Dr. Wellness. Its listed ingredients include amla, cumin, and black pepper. The semaglutide and tirzepatide studies discussed in this article did not evaluate GluSlim, and its effectiveness for maintaining weight loss after GLP‑1 treatment has not been established. If you’re considering GluSlim after stopping an injection, bring the full ingredient list to your clinician or pharmacist before starting. They can review it in light of your health history and any medicines you take. GluSlim product page and full ingredient list

Conclusion

Before the last injection, agree with your prescriber on when you’ll check in, what you’ll monitor, and who you’ll contact if your appetite, weight, or blood glucose changes. At that first follow-up, talk through what has happened in daily life and which parts of the plan have been difficult to keep. That conversation can guide whether you need more nutrition support, a structured programme, or a review of treatment options. NICE guidance on weight maintenance and follow-up

Medical disclaimer. This article is for general education and does not provide individual medical advice. Speak with your prescriber before stopping or changing a GLP‑1–based medicine. Consult a clinician or pharmacist before starting a supplement, particularly if you take medication for diabetes. GluSlim should never replace prescribed treatment.

Commercial disclosure. Dr. Wellness publishes this article and sells GluSlim.

References

1. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022. STEP 1 trial extension

2. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity. JAMA. 2024. SURMOUNT‑4 randomized clinical trial

3. West S, et al. Weight regain after cessation of medication for weight management. The BMJ. 2026. Systematic review and meta-analysis

4. National Institute for Health and Care Excellence. Overweight and obesity management. Medicines and surgery · Physical activity and diet · Support after stopping weight-management medicines